Eikon Therapeutics Statistics
Total Valuation
EIKN has a market cap or net worth of $463.43 million. The enterprise value is $375.03 million.
Important Dates
The last earnings date was Monday, March 30, 2026, before market open.
| Earnings Date | Mar 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EIKN has 54.14 million shares outstanding.
| Current Share Class | 54.14M |
| Shares Outstanding | 54.14M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +13.21% |
| Owned by Insiders (%) | 5.89% |
| Owned by Institutions (%) | 9.37% |
| Float | 27.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.91.
| Current Ratio | 6.34 |
| Quick Ratio | 6.11 |
| Debt / Equity | 0.91 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -375.66 |
Financial Efficiency
Return on equity (ROE) is -125.02% and return on invested capital (ROIC) is -40.17%.
| Return on Equity (ROE) | -125.02% |
| Return on Assets (ROA) | -36.19% |
| Return on Invested Capital (ROIC) | -40.17% |
| Return on Capital Employed (ROCE) | -58.26% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$868,865 |
| Employee Count | 384 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 11.97 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 34.35 |
| Average Volume (20 Days) | 288,632 |
Short Selling Information
The latest short interest is 3.56 million, so 6.57% of the outstanding shares have been sold short.
| Short Interest | 3.56M |
| Short Previous Month | 3.31M |
| Short % of Shares Out | 6.57% |
| Short % of Float | 12.93% |
| Short Ratio (days to cover) | 8.21 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -314.43M |
| Pretax Income | -324.25M |
| Net Income | -333.64M |
| EBITDA | -295.55M |
| EBIT | -314.43M |
| Earnings Per Share (EPS) | -$115.29 |
Full Income StatementBalance Sheet
The company has $335.98 million in cash and $257.32 million in debt, giving a net cash position of $78.66 million or $1.45 per share.
| Cash & Cash Equivalents | 335.98M |
| Total Debt | 257.32M |
| Net Cash | 78.66M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 282.44M |
| Book Value Per Share | -286.47 |
| Working Capital | 293.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$188.52 million and capital expenditures -$46.74 million, giving a free cash flow of -$235.26 million.
| Operating Cash Flow | -188.52M |
| Capital Expenditures | -46.74M |
| Depreciation & Amortization | 18.87M |
| Net Borrowing | n/a |
| Free Cash Flow | -235.26M |
| FCF Per Share | -$4.35 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |